Gilead's sofosbuvir gets EMA validation, now under assessment
The Fly on the Wall
Racing Toward the Next Hepatitis C Drug Approval
Motley Fool
[video]FDA Prioritizes New Hepatitis C Drug
Motley Fool
Gilead's Hepatitis C Drug Sofosbuvir Offers Upside
Seeking Alpha
Gilead's HCV Drug Pipeline Outshines Weak Q1 Results
Investors.com

